Cargando…

Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study

The effect of coronavirus disease (COVID-19) on the risk of relapse in multiple sclerosis (MS) have been unknown. In this retrospective study of 41 relapsing-remitting MS patients, number of relapses in pre-defined at risk-period (ARP) was compared with the previous two years. During the previous tw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barzegar, Mahdi, Vaheb, Saeed, Mirmosayyeb, Omid, Afshari-Safavi, Alireza, Nehzat, Nasim, Shaygannejad, Vahid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier B.V. 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036166/ https://www.ncbi.nlm.nih.gov/pubmed/33979771 http://dx.doi.org/10.1016/j.msard.2021.102947

Ejemplares similares

COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review
por: Barzegar, Mahdi, et al.
Publicado: (2021)

Characteristics of COVID-19 disease in multiple sclerosis patients
por: Barzegar, Mahdi, et al.
Publicado: (2020)

Evaluation of Month of Birth in Neuromyelitis Optica Spectrum Disorders (NMSOD) and Multiple Sclerosis (MS)
por: Mirmosayyeb, Omid, et al.
Publicado: (2021)

Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis
por: Mirmosayyeb, Omid, et al.
Publicado: (2020)

Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2020)

Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset
por: Sadeghi-Bahmani, Dena, et al.
Publicado: (2022)

Higher Disease and Pain Severity and Fatigue and Lower Balance Skills Are Associated with Higher Prevalence of Falling among Individuals with the Inflammatory Disease of Neuromyelitis Optica Spectrum Disorder (NMOSD)
por: Barzegar, Mahdi, et al.
Publicado: (2020)

Association of helicobacter pylori with multiple sclerosis: Protective or risk factor?
por: Mirmosayyeb, Omid, et al.
Publicado: (2020)

Olfactory dysfunction in patients with multiple sclerosis; A systematic review and meta-analysis
por: Mirmosayyeb, Omid, et al.
Publicado: (2022)

Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
por: Nehzat, Nasim, et al.
Publicado: (2021)

Demographic and Clinical Characteristics of Familial and Sporadic Multiple Sclerosis Patients
por: Mokhtari, Shahrzad, et al.
Publicado: (2023)

COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
por: Barzegar, Mahdi, et al.
Publicado: (2020)

Screening neuromyelitis optica patients for COVID-19 infection
por: Mirmosayyeb, Omid, et al.
Publicado: (2020)

Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis
por: Vaheb, Saeed, et al.
Publicado: (2023)

Fear of relapse, social support, and psychological well-being (depression, anxiety, and stress level) of patients with multiple sclerosis (MS) during the COVID-19 pandemic stage
por: Shaygannejad, Vahid, et al.
Publicado: (2021)

Prevalence of Seizure/Epilepsy in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis
por: Mirmosayyeb, Omid, et al.
Publicado: (2021)

COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis
por: Barzegar, Mahdi, et al.
Publicado: (2022)

Assessment of mental health, knowledge, and attitude of patients with multiple sclerosis and neuromyelitis optica spectrum disorder in response to 2019 novel coronavirus
por: Shaygannejad, Vahid, et al.
Publicado: (2020)

Association of Disease-Modifying Therapies with COVID-19 Susceptibility and Severity in Patients with Multiple Sclerosis: A Systematic Review and Network Meta-Analysis
por: Barzegar, Mahdi, et al.
Publicado: (2022)

Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study
por: Barzegar, Mahdi, et al.
Publicado: (2023)

Psychometric assessment of the Persian version of the patient determined disease steps scale in patients with multiple sclerosis and neuromyelitis optica spectrum disorder
por: Mirmosayyeb, Omid, et al.
Publicado: (2022)

Bell's palsy after Sputnik V COVID‐19 (Gam‐COVID‐Vac) vaccination
por: Mirmosayyeb, Omid, et al.
Publicado: (2022)

Risk and severity of SARS-CoV-2 reinfection among patients with multiple sclerosis vs. the general population: a population-based study
por: Barzegar, Mahdi, et al.
Publicado: (2022)

Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccines: A systematic review
por: Mirmosayyeb, O., et al.
Publicado: (2023)

MS Care in Novel Coronavirus 19 Pandemic
por: Ramezani, Neda, et al.
Publicado: (2020)

Managing anxiety among multiple sclerosis patients during COVID-19 pandemic
por: Adibi, Iman, et al.
Publicado: (2021)

Psychometric Properties of the Persian Version of the Multiple Sclerosis Work Difficulties Questionnaire (MSWDQ) Questionnaire
por: Mirmosayyeb, Omid, et al.
Publicado: (2022)

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review
por: Mirmosayyeb, Omid, et al.
Publicado: (2023)

Comparison of Cognitive Rehabilitation versus Donepezil Therapy on Memory Performance, Attention, Quality of Life, and Depression among Multiple Sclerosis Patients
por: Shahpouri, Mohammad Mahdi, et al.
Publicado: (2020)

Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study
por: Sedaghat, Nahad
Publicado: (2021)

Comparison of Psychological Difficulties in Patients with Migraine and Epilepsy Using PARADISE-24 Questionnaire
por: Mirmosayyeb, Omid, et al.
Publicado: (2020)

Acute CNS demyelination in a subject with cerebellar ataxia following the first dose of COVID-19 vaccine; a case report
por: Mirmosayyeb, Omid, et al.
Publicado: (2021)

Fear of re-infection, relapse, and anxiety during COVID-19 pandemic in patients with multiple sclerosis: A multi-center study
por: Moghadasi, Abdorreza Naser, et al.
Publicado: (2023)

Predictors of Catching COVID-19 Infection during Pandemic Stage in Patients with Multiple Sclerosis (MS)
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2022)

ADAR Expression and Single Nucleotide Variants in Multiple Sclerosis Patients Affect the Response to Interferon Beta Therapy
por: Fakhr, Fatemeh, et al.
Publicado: (2023)

The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): A systematic review and meta-analysis
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2021)

The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis
por: Moghadasi, Abdorreza Naser, et al.
Publicado: (2021)

Comparison of follicular T helper cells, monocytes, and T cells priming between newly diagnosed and rituximab-treated MS patients and healthy controls
por: Yahyazadeh, Sheida, et al.
Publicado: (2022)

CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series
por: Ebrahimi, Narges, et al.
Publicado: (2023)

Editorial: CNS autoimmune disorders and COVID-19
por: Mirmosayyeb, Omid, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uhf44iuvfot6f8kpqbu7v8p71i